Why Environmentalists Should Be Concerned
By Bill McKibben,
WorldWatch
| 06. 30. 2002
July / August 2002
It's not as if environmentalists really need something new to worry about. The planet's temperature is set to rise four or five degrees-every glacial system is already in rapid retreat, and icebergs measured in units of U.S. states (the size of Rhode Island!) are calving off the Antarctic. Species disappear daily; acid rain; and you know the whole damn litany. We could be forgiven for wanting to take a pass on human genetic engineering.
And yet I think it may turn into the single greatest battle environmentalists have ever fought, the one for which the Grand Canyon and the African elephants and Amazon deforestation and Love Canal were preparing us. The real test.
Some of the reasons for thinking so are pragmatic. Changing the human germline is an almost preposterous override of the precautionary principle, the idea that if you don't know something's safe you shouldn't do it. We have rushed with blinding speed through the first phases of the biotechnological revolution-what was experimental a decade ago now grows in half the corn and soybean fields...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...